Welcome to the e-CCO Library!

DOP001: Effectiveness and safety of vedolizumab in anti-TNF naïve patients with inflammatory bowel disease: a multicentre retrospective European Crohn’s and Colitis Organisation study
Year: 2018
Source: ECCO '18 Vienna
Authors:

U. Kopylov1*, B. Verstockt2, L. Biedermann3, S. Sebastian4, D. Pugliese5, E. Sonnenberg6, P.R. Steinhagen6, N. Arebi7, Y. Ron8, T. Kucharzik9, X. Roblin10, B. Ungar1, A. Bar-Gil Shitrit11, S. Ardizzone12, P. Molander13, M. Coletta14, L. Peyrin-Biroulet15, P. Bossuyt16, I. Avni-Biron17, E.I. Tsoukal18, M. Allocca19, K. Katsanos20, T. Raine21, T. Sipponen22, G. Fiorino23, S. Ben-Horin1, R. Eliakim1, A. Armuzzi5, B. Siegmund6, D.C. Baumgart6, N. Kamperidis7, N. Maharshak8, C. Maaser9, G. Mantzaris18, H. Yanai17, D. Christodoulou20, I. Dotan17, M. Ferrante2

Created: Thursday, 21 February 2019, 9:14 AM
DOP001: European Crohn's and Colitis Organisation topical review on environmental factors in IBD
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Maaser C.*1, Langholz E.2, Gordon H.3, Burisch J.4, Ellul P.5, Hernández V.6, Karakan T.7, Katsanos K.H.8, Krustins E.9, Levine A.10, Mantzaris G.J.11, O'Morain C.12, Yuksel E.S.13, Strid H.14, Annese V.15

Created: Wednesday, 20 February 2019, 10:36 AM
DOP001: Genetic and environmental risk model to predict intestinal inflammation in asymptomatic first-degree relatives of Crohns disease patients
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

K. M. Taylor*1, 2, N.S. Taylor3, S. H. Anderson1, P. M. Irving1, N. J. Prescott2, C. M. Lewis2, C. G. Mathew2, J. D. Sanderson1

Created: Friday, 22 February 2019, 9:49 AM
DOP002: Molecular response to ustekinumab in moderate-to-severe Crohns disease by serum protein analysis: results from the UNITI-1 and UNITI-2 Phase 3 induction studies
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

K. Li*, K. Hayden, E. Wadman, S. Bhagat, S. Emrich, J. R. Friedman, C. Gasink, C. Brodmerkel

Created: Friday, 22 February 2019, 9:49 AM
DOP002: Trends in small bowel resections for Crohn's disease with and without short bowel syndrome in the era of biologics
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Limketkai B.1, Parian A.2, Colombel J.-F.*3

Created: Wednesday, 20 February 2019, 10:36 AM
DOP002: Vedolizumab treatment persistence up to 3 years: post hoc analysis in vedolizumab-naïve patients from the GEMINI LTS study
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Vermeire1*, E.V. Loftus Jr.2, J.M. Khalid3, D. Tudor4, M. Akbari5, D. Demuth3, L. Peyrin-Biroulet6

Created: Thursday, 21 February 2019, 9:14 AM
DOP003: Gene expression profiling indicates similar molecular pathways are active in adult and paediatric ulcerative colitis
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

K. Li*1, J. Ouahed2, J. Friedman1, R. Strauss1, D. Chan1, S. Telesco1, D. Shouval3, J. Canavan4, C. Brodmerkel1, S. Snapper5

Created: Friday, 22 February 2019, 9:49 AM
DOP003: Proximal disease extension in patients with limited ulcerative colitis: a Danish population-based inception cohort
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Burisch J.*1, Vind I.2, Prosberg M.2, Colombel J.-F.3, Ungaro R.3, Bendtsen F.2, Vester-Andersen M.2,4

Created: Wednesday, 20 February 2019, 10:36 AM
DOP003: Ustekinumab induces clinical and biological remission in biologic refractory Crohn’s disease patients: A real-world belgian cohort study
Year: 2018
Source: ECCO '18 Vienna
Authors:

C. Liefferinckx1,2*, B. Verstockt3, A. Gils4, M. Noman3, C. Van Kemseke5, E. Macken6, M. De Vos7, W. Van Moerkercke8, J.-F. Rahier9, P. Bossuyt10, J. Dutré11, E. Humblet12, D. Staessen13, H. Peeters14, P. Van Hootegem15, E. Louis5, D. Franchimont1,2, F. Baert16, S. Vermeire3

Created: Thursday, 21 February 2019, 9:14 AM
DOP004: Epigenetic control of colonic epithelial antigen processing, barrier function, and the microbiome via methyl-CpG binding domain protein 2
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

G.-R. Jones*1, A. MacDonald2, P. Cook2

Created: Friday, 22 February 2019, 9:49 AM
DOP004: Ethnicity and country of birth are associated with phenotypic differences in patients with inflammatory bowel disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Spekhorst L.*1,2, Severs M.3, de Boer N.K.H.4, Festen E.A.M.1,2, Fidder H.H.3, Hoentjen F.5, Imhann F.1,2, de Jong D.J.5, van der Meulen-de Jong A.E.6, Pierik M.7, van der Woude C.J.8, Dijkstra G.1, Ponsioen C.Y.9, Lowenberg M.9, Oldenburg B.3, Weersma R.K.1

Created: Wednesday, 20 February 2019, 10:36 AM
DOP004: Long-term safety of adalimumab in patients with moderate-to-severe ulcerative colitis: Interim results of a non-interventional registry, LEGACY
Year: 2018
Source: ECCO '18 Vienna
Authors:

P. Bossuyt1*, R. Atreya2, C. Taxonera3,4, X. Hebuterne5,6, K. Isaacs7, P.D. Higgins8, J. Lindsay9, G. Heap10, D. Arikan10, V. Kuehnl11, J. Petersson10, A.M. Robinson10, E.V. Loftus Jr.12

Created: Thursday, 21 February 2019, 9:14 AM
DOP005: A role for IL1 in mediating intestinal inflammation in IL10 receptor deficiency in mice and humans
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

D. Shouval*1, 2, A. Biswas2, Y.-H. Kang2, A. Griffith2, B. Horwitz2, A. Bousvaros2, S. Snapper2

Created: Friday, 22 February 2019, 9:49 AM
DOP005: Proximal disease extension in limited ulcerative colitis: a systematic review and meta-analysis
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Roda G.*1, Narula N.2, Pinotti R.3, Skamnelos A.4, Katsanos K.4, Torres J.5, Ungaro R.6, Colombel J.-F.7

Created: Wednesday, 20 February 2019, 10:36 AM
DOP005: Safety of vedolizumab in patients naïve to treatment with TNF antagonists compared with patients with prior use of TNF antagonists
Year: 2018
Source: ECCO '18 Vienna
Authors:

R. Cohen1, F. Bhayat2*, G. Hantsbarger2, A. Blake3, S. Vermeire4

Created: Thursday, 21 February 2019, 9:14 AM
DOP006: A multicentre cohort study to assess the safety of vedolizumab for inflammatory bowel disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

J. Meserve1, S. Aniwan2, J.L. Koliani-Pace3, P. Shashi4, A. Weiss5, D. Faleck6, A. Winters6, S. Chablaney6, G. Kochhar4, B. Boland1, S. Singh1, R. Hirten6, E. Shmidt6, M. Bohm7, S. V Sagi7, M. Fischer7, D. Lukin5, D. Hudesman8, S. Chang8, K. Sultan9, A. Swaminath10, N. Gupta11, S. Kane2, E.V. Loftus2, B. Shen4, B.E. Sands6, J.-F. Colombel6, C.A. Siegel3, W.J. Sandborn1, P.S. Dulai1*

Created: Thursday, 21 February 2019, 9:14 AM
DOP006: Gut-homing adipose tissue T-cells might influence intestinal barrier function in Crohns disease and obesity
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

L. J. Jödicke*1, L. I. Kredel1, A. A. Kuehl1, I. Freise1, J. Gröne2, J. Ordemann3, B. Siegmund1

Created: Friday, 22 February 2019, 9:49 AM
DOP006: Research gaps in diet and nutrition in inflammatory bowel disease. A topical review by ECCO
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Sigall Boneh R.1, Levine A.1,2, Lomer M.3, Wierdsma N.4, Alan P.5, Fiorino G.6, Gatti S.7, Jonkers D.8, Kierkus J.9, Katsanos K.H.10, Melgar S.11, Saritas Yuksel E.12, Whelan K.13, Wine E.14, Gerasimidis K.*15

Created: Wednesday, 20 February 2019, 10:36 AM
DOP007: Crohn's disease exclusion diet and partial enteral nutrition (CDED+PEN) vs exclusive enteral nutrition (EEN). Microbiome changes of a randomized clinical trial (RCT) in pediatric CD: remission is associated with similar structural + functional profiles
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Dunn K.A.1, Sigall-Boneh R.2, Bielawski J.P.1, Turner D.3, Van Limbergen J.*4, Levine A.2

Created: Wednesday, 20 February 2019, 10:36 AM
DOP007: Efficacy of vedolizumab induction therapy on clinical and endoscopic activity in patients with anti-tumour necrosis factor alpha-resistant inflammatory bowel disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

R. Bor1*, F. Klaudia2, P. Miheller3, K. Palatka4, T. Szamosi5, Á. Vincze6, M. Rutka7, K. Szántó2, A. Bálint2, Z. Szepes2, F. Nagy2, Á. Milassin2, A. Fábián2, Á. Csontos3, P. Golovics5, L. Lakner8, K. Müllner3, M. Papp9, Á. Salamon10, K. Sarang8, Z. Vitális4, E. Schafer11, P. Sarlós6, T. Molnár2

Created: Thursday, 21 February 2019, 9:14 AM